We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-0.68%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.76B
AUM Growth
-$304M
Cap. Flow
+$23.1M
Cap. Flow %
0.49%
Top 10 Hldgs %
26.26%
Holding
167
New
11
Increased
69
Reduced
16
Closed
14

Top Buys

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$35.6M
2
WRBY icon
Warby Parker
WRBY
+$35M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$30.4M
4
IMRX icon
Immuneering
IMRX
+$29.3M
5
ABOS icon
Acumen Pharmaceuticals
ABOS
+$26.3M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$68.6M
2
ARDX icon
Ardelyx
ARDX
+$39.8M
3
BIIB icon
Biogen
BIIB
+$39.3M
4
BSX icon
Boston Scientific
BSX
+$34.2M
5
PPD
PPD, Inc. Common Stock
PPD
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 93.24%
2 Consumer Staples 1.58%
3 Industrials 0.82%
4 Financials 0.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MIRM icon
51
Mirum Pharmaceuticals
MIRM
$6.02B
$30.4M 0.64%
1,525,623
+1,900
+0.1% +$30.9K
CVET
52
DELISTED
Covetrus, Inc. Common Stock
CVET
$29.4M 0.62%
1,623,500
+168,500
+12% +$3.86M
IMRX icon
53
Immuneering
IMRX
$293M
$28.9M 0.61%
+1,089,816
New +$29.3M
SRRA
54
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$28.8M 0.61%
1,313,997
+295,339
+29% +$5.91M
MRSN
55
DELISTED
Mersana Therapeutics
MRSN
$28.5M 0.6%
120,828
+7,003
+6% +$2.05M
DVAX
56
DELISTED
Dynavax Technologies
DVAX
$27.5M 0.58%
1,429,921
-250,000
-15% -$3.32M
AVIR icon
57
Atea Pharmaceuticals
AVIR
$402M
$26.3M 0.55%
750,307
-40,826
-5% -$1.13M
IRTC icon
58
iRhythm Holdings
IRTC
$4.1B
$26.2M 0.55%
448,000
– –
DXCM icon
59
DexCom
DXCM
$33.1B
$25.4M 0.53%
186,000
+3,600
+2% +$454K
LUNG icon
60
Pulmonx
LUNG
$97.9M
$25.2M 0.53%
700,000
+107,500
+18% +$4.23M
GH icon
61
Guardant Health
GH
$22.4B
$25M 0.53%
200,000
– –
LFST icon
62
Lifestance Health
LFST
$4.55B
$24.5M 0.51%
1,687,500
+187,500
+13% +$3.61M
CGEM icon
63
Cullinan Oncology
CGEM
$1.18B
$24.3M 0.51%
1,075,912
– –
ABOS icon
64
Acumen Pharmaceuticals
ABOS
$176M
$23.5M 0.49%
+1,579,191
New +$26.3M
ABCM
65
DELISTED
Abcam PLC
ABCM
$23.3M 0.49%
1,147,588
+50,088
+5% +$997K
WHWK
66
Whitehawk Therapeutics
WHWK
$259M
$22.5M 0.47%
764,701
+755,809
+8,500% +$23M
AMRN
67
Amarin Corp
AMRN
$298M
$22M 0.46%
216,000
– –
ICVX
68
DELISTED
Icosavax, Inc. Common Stock
ICVX
$21.7M 0.46%
+734,215
New +$24.9M
CNMD icon
69
CONMED
CNMD
$1.48B
$21.3M 0.45%
162,500
– –
MDGL icon
70
Madrigal Pharmaceuticals
MDGL
$11.9B
$20.9M 0.44%
262,500
– –
BOLT icon
71
Bolt Biotherapeutics
BOLT
$7.67M
$20.9M 0.44%
82,462
+1,500
+2% +$424K
NVCR icon
72
NovoCure
NVCR
$2.02B
$20.3M 0.43%
175,000
– –
BMRN icon
73
BioMarin Pharmaceuticals
BMRN
$13.3B
$19.6M 0.41%
253,500
– –
OSH
74
DELISTED
Oak Street Health, Inc.
OSH
$18.8M 0.39%
441,000
+66,000
+18% +$3.55M
EPZM
75
DELISTED
Epizyme, Inc
EPZM
$18.4M 0.39%
3,593,885
+582,398
+19% +$3.54M
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Rock Springs Capital Management held 167 positions worth $4.76B, down 6% from $5.06B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rock Springs Capital Management's Q3 2021 filing shows 11 new, 69 increased, 16 reduced and 14 closed positions. Its largest new stake was Baxter International: 450,000 shares worth $36.2M. The largest sale was BeOne Medicines Ltd, an estimated $68.6M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q3 2021 buy was Baxter International: 450,000 shares worth $36.2M.
  • Rock Springs Capital Management added most to Ultragenyx Pharmaceutical in Q3 2021, an estimated $30.4M increase.
  • Rock Springs Capital Management's biggest Q3 2021 reduction was Prothena Corp, cutting an estimated $14.9M.
  • Rock Springs Capital Management fully exited BeOne Medicines Ltd in Q3 2021, selling an estimated $68.6M.
  • Rock Springs Capital Management's ten largest holdings make up 26% of its $4.76B portfolio in Q3 2021.
  • Rock Springs Capital Management opened 11 new positions and closed 14 in Q3 2021.
  • Rock Springs Capital Management's portfolio value fell 6% quarter-over-quarter to $4.76B.

Based on Rock Springs Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.